Source: Annual Congress 2002 - Thoracic oncology: diagnosis and prognosis
Disease area: Thoracic oncology

Abstract

MDM2 is a proto-oncogene frequently amplified in human sarcomas. Since the prognostic value of MDM2 amplification in NSCLC is unknown, we investigated this issue in 116 NSCLC patients who underwent pulmonary resection. MDM2 amplification was assessed by Real Time - PCR LightCycler Technology. Osteosarcoma cell line and placenta cells served as positive and negative controls, respectively. The values of >20% were considered positive, based on the distance between negative and positive control ratios. MDM2 amplification was found in 24 patients (21%). There was no relationship between MDM2 amplification and major patient characteristics. Median disease-free survival for patients with and without MDM2 amplification was 5 months and 40 months, respectively, and five-year disease-free survival probability was 22% and 48%, respectively (chi2; p=0.004). Median overall survival for patients with and without MDM2 amplification was 11 months and 43 months, respectively and five-year survival probability was 26% and 45%, respectively (chi2; p=0.008). In multivariate analysis significant factors for disease-free survival included stage of disease and the presence of MDM2 amplification (p=0.04 and p=0.002, respectively), and there was a trend towards decreased overall survival and MDM2 amplification (p=0.078). These results indicate adverse prognostic impact of MDM2 amplification in operable NSCLC.

Rating:

Share or cite this content

Citations should be made in the following way:
D. Dworakowska, R. Schneider-Stock, E. Jassem, B. Peters, M. Zylicz, J. Limon, J. Jakobkiewicz, G. Kobierska, A. Szymanowska, J. Skokowski, A. Roessner, J. Jassem (Gdansk, Poland; Magdeburg, Germany). MDM-2 gene amplification is associated with poor prognosis in operable non-small cell lung cancer (NSCLC). Eur Respir J 2002; 20: Suppl. 38, 3726

Member's Comments

No comment yet.

Related content which might interest you: Fascin-1 overexpression predicts a poor prognosis in non-small cell lung cancer Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Investigation of survivin gene polymorphism in non-small cell lung cancer patients (NSCLC) Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Analysis of the prognosis value of the mitochondrial activity in resected non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer Year: 2009 24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC) Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status Source: Annual Congress 2011 - Epidemiology of lung cancer and screening Year: 2011 p-53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer Source: Annual Congress 2007 - Novel genetic markers in pathology Year: 2007 A variant in LKB1 gene can predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018 p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001 How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations Source: International Congress 2015 – How to treat brain metastases Year: 2015 Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007 Her/2 neu and p53 expression in patients with non-small cell lung cancer predict shortened survival Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 Prognostic significance of p53 and bcl-2 abnormalities in operable non-small cell lung cancer Source: Eur Respir J 2001; 17: 660-666 Year: 2001 TNFα as a prognostic factor in surgically treated non-small cell lung carcinomas Source: Annual Congress 2005 - Management of lung cancer: clinical problems Year: 2005 TTF-1 for prediction of response to chemotherapy in patients with locally advanced or metastatic small cell lung cancer (SCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Clinical relevance of p53 and K-ras mutations in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001 The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival Source: Eur Respir J 2007; 30: Suppl. 51, 280s Year: 2007 Influence of histological subtypes of bronchioloalveolar carcinoma on prognosis and treatment Source: Annual Congress 2006 - Prognostic factors in lung cancer Year: 2006 XAGE-1b and p53: Potential targets for immunotherapy of non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012